Becker's Healthcare February 16, 2024
Erica Carbajal

The FDA has approved omalizumab, which goes by the brand name Xolair, as a treatment to reduce the risk of severe allergic reactions for those with food allergies.

The drug, a prescription biologic medicine given as an injection under the skin, was approved as a treatment to cut the risk of allergic reactions that may occur among people age 1 and older with IgE-mediated food allergies, which are the most common type.

The drug is not intended to to be used as an emergency treatment of allergic reactions, and people taking the drug should continue to avoid foods...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
5 Digital Health Areas To Be Impacted By The FDA Layoffs
FDA Approves First Biosimilar to Omalizumab
Trump's Nominees to Run FDA, NIH Get Greenlighted by Senate Committee
FDA Debuts a New Communications and Compliance Tool for Device Data Integrity Concerns
HHS Explores Stronger FDA Oversight for Food Ingredients

Share This Article